Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelofibrosis (including after a blood disorder called polycythemia vera or essential thrombocythemia).
- Your spleen is enlarged (at least 450 cm³ on an MRI or CT scan).
- Your platelet count is 50,000 or higher (without a transfusion in the last 7 days).
- You have not been treated with a JAK inhibitor (like ruxolitinib or fedratinib) before.
- You are not eligible for a stem cell transplant (bone marrow transplant).
- You have symptoms from myleofibrosis that affect your daily life, like fever, night sweats, or bone pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.